Zelira Therapeutics OTC Stock Forward View - Simple Moving Average
| ZLDAF Stock | USD 0.27 0.00 0.00% |
Zelira OTC Stock outlook is based on your current time horizon. We recommend always using this module together with an analysis of Zelira Therapeutics' historical fundamentals, such as revenue growth or operating cash flow patterns.
As of 31st of January 2026 The value of RSI of Zelira Therapeutics' share price is above 80 . This usually means that the otc stock is significantly overbought by investors. The fundamental principle of the Relative Strength Index (RSI) is to quantify the velocity at which market participants are driving the price of a financial instrument upwards or downwards. Momentum 83
Buy Peaked
Oversold | Overbought |
It is a matter of debate whether otc price prediction based on information in financial news can generate a strong buy or sell signal. We use our internally-built news screening methodology to estimate the value of Zelira Therapeutics based on different types of headlines from major news networks to social media. Using Zelira Therapeutics hype-based prediction, you can estimate the value of Zelira Therapeutics Limited from the perspective of Zelira Therapeutics response to recently generated media hype and the effects of current headlines on its competitors.
The Simple Moving Average forecasted value of Zelira Therapeutics Limited on the next trading day is expected to be 0.27 with a mean absolute deviation of 0 and the sum of the absolute errors of 0.14. Zelira Therapeutics after-hype prediction price | USD 0.27 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as otc price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Zelira |
Zelira Therapeutics Additional Predictive Modules
Most predictive techniques to examine Zelira price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Zelira using various technical indicators. When you analyze Zelira charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Zelira Therapeutics Simple Moving Average Price Forecast For the 1st of February
Given 90 days horizon, the Simple Moving Average forecasted value of Zelira Therapeutics Limited on the next trading day is expected to be 0.27 with a mean absolute deviation of 0, mean absolute percentage error of 0.000057, and the sum of the absolute errors of 0.14.Please note that although there have been many attempts to predict Zelira OTC Stock prices using its time series forecasting, we generally do not recommend using it to place bets in the real market. The most commonly used models for forecasting predictions are the autoregressive models, which specify that Zelira Therapeutics' next future price depends linearly on its previous prices and some stochastic term (i.e., imperfectly predictable multiplier).
Zelira Therapeutics OTC Stock Forecast Pattern
| Backtest Zelira Therapeutics | Zelira Therapeutics Price Prediction | Buy or Sell Advice |
Zelira Therapeutics Forecasted Value
In the context of forecasting Zelira Therapeutics' OTC Stock value on the next trading day, we examine the predictive performance of the model to find good statistically significant boundaries of downside and upside scenarios. Zelira Therapeutics' downside and upside margins for the forecasting period are 0 and 3.26, respectively. We have considered Zelira Therapeutics' daily market price to evaluate the above model's predictive performance. Remember, however, there is no scientific proof or empirical evidence that traditional linear or nonlinear forecasting models outperform artificial intelligence and frequency domain models to provide accurate forecasts consistently.
Model Predictive Factors
The below table displays some essential indicators generated by the model showing the Simple Moving Average forecasting method's relative quality and the estimations of the prediction error of Zelira Therapeutics otc stock data series using in forecasting. Note that when a statistical model is used to represent Zelira Therapeutics otc stock, the representation will rarely be exact; so some information will be lost using the model to explain the process. AIC estimates the relative amount of information lost by a given model: the less information a model loses, the higher its quality.| AIC | Akaike Information Criteria | 104.6658 |
| Bias | Arithmetic mean of the errors | -0.0013 |
| MAD | Mean absolute deviation | 0.0023 |
| MAPE | Mean absolute percentage error | 0.0096 |
| SAE | Sum of the absolute errors | 0.135 |
Predictive Modules for Zelira Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Zelira Therapeutics. Regardless of method or technology, however, to accurately forecast the otc stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the otc stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Zelira Therapeutics After-Hype Price Density Analysis
As far as predicting the price of Zelira Therapeutics at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Zelira Therapeutics or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of OTC Stock prices, such as prices of Zelira Therapeutics, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
Zelira Therapeutics Estimiated After-Hype Price Volatility
In the context of predicting Zelira Therapeutics' otc stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Zelira Therapeutics' historical news coverage. Zelira Therapeutics' after-hype downside and upside margins for the prediction period are 0.01 and 3.26, respectively. We have considered Zelira Therapeutics' daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
Zelira Therapeutics is out of control at this time. Analysis and calculation of next after-hype price of Zelira Therapeutics is based on 3 months time horizon.
Zelira Therapeutics OTC Stock Price Outlook Analysis
Have you ever been surprised when a price of a OTC Stock such as Zelira Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Zelira Therapeutics backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the OTC price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Zelira Therapeutics, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.36 | 2.99 | 0.00 | 0.00 | 0 Events / Month | 0 Events / Month | Any time |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | |
0.27 | 0.27 | 0.00 |
|
Zelira Therapeutics Hype Timeline
Zelira Therapeutics is at this time traded for 0.27. The entity stock is not elastic to its hype. The average elasticity to hype of competition is 0.0. Zelira is forecasted not to react to the next headline, with the price staying at about the same level, and average media hype impact volatility is insignificant. The immediate return on the next news is forecasted to be very small, whereas the daily expected return is at this time at 0.36%. %. The volatility of related hype on Zelira Therapeutics is about 0.0%, with the expected price after the next announcement by competition of 0.27. About 44.0% of the company outstanding shares are owned by insiders. The company has Price to Book (P/B) ratio of 0.29. Historically many companies with similar price-to-book (P/B) ratio do better than the market in the long run. Zelira Therapeutics recorded a loss per share of 1.05. The entity had not issued any dividends in recent years. The firm had 1:175 split on the 14th of April 2022. Assuming the 90 days horizon the next forecasted press release will be any time. Check out Historical Fundamental Analysis of Zelira Therapeutics to cross-verify your projections.Zelira Therapeutics Related Hype Analysis
Having access to credible news sources related to Zelira Therapeutics' direct competition is more important than ever and may enhance your ability to predict Zelira Therapeutics' future price movements. Getting to know how Zelira Therapeutics' peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Zelira Therapeutics may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| PKTX | Protokinetix | 0.00 | 0 per month | 10.93 | 0.09 | 21.82 | (16.67) | 58.05 | |
| ARUXF | Acrux Limited | 0.00 | 0 per month | 0.00 | 0.10 | 0.00 | (19.00) | 272.22 | |
| AXIM | Axim Biotechnologies | 0.00 | 0 per month | 8.97 | 0.13 | 21.43 | (15.79) | 76.67 | |
| HAVLF | HAVN Life Sciences | 0.00 | 0 per month | 0.00 | 0.11 | 0.00 | 0.00 | 1,895 | |
| AGNPF | Algernon Pharmaceuticals | 0.00 | 0 per month | 0.00 | (0.06) | 14.10 | (13.67) | 31.25 | |
| SIGY | Sigyn Therapeutics | 0.00 | 0 per month | 0.00 | (0.05) | 25.00 | (30.00) | 98.12 | |
| RNUGF | ReNeuron Group Plc | 0.00 | 0 per month | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| REPCF | RepliCel Life Sciences | 0.00 | 0 per month | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| APLIF | Appili Therapeutics | 0.00 | 0 per month | 7.06 | 0 | 20.00 | (16.67) | 42.48 | |
| RDDTF | Radient Technologies | 0.00 | 0 per month | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Forecasting Options for Zelira Therapeutics
For every potential investor in Zelira, whether a beginner or expert, Zelira Therapeutics' price movement is the inherent factor that sparks whether it is viable to invest in it or hold it better. Zelira OTC Stock price charts are filled with many 'noises.' These noises can hugely alter the decision one can make regarding investing in Zelira. Basic forecasting techniques help filter out the noise by identifying Zelira Therapeutics' price trends.Zelira Therapeutics Related Equities
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Zelira Therapeutics otc stock to make a market-neutral strategy. Peer analysis of Zelira Therapeutics could also be used in its relative valuation, which is a method of valuing Zelira Therapeutics by comparing valuation metrics with similar companies.
| Risk & Return | Correlation |
Zelira Therapeutics Market Strength Events
Market strength indicators help investors to evaluate how Zelira Therapeutics otc stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Zelira Therapeutics shares will generate the highest return on investment. By undertsting and applying Zelira Therapeutics otc stock market strength indicators, traders can identify Zelira Therapeutics Limited entry and exit signals to maximize returns.
Zelira Therapeutics Risk Indicators
The analysis of Zelira Therapeutics' basic risk indicators is one of the essential steps in accurately forecasting its future price. The process involves identifying the amount of risk involved in Zelira Therapeutics' investment and either accepting that risk or mitigating it. Along with some essential techniques for forecasting zelira otc stock prices, we also provide a set of basic risk indicators that can assist in the individual investment decision or help in hedging the risk of your existing portfolios.
| Mean Deviation | 0.9604 | |||
| Standard Deviation | 2.94 | |||
| Variance | 8.66 |
Please note, the risk measures we provide can be used independently or collectively to perform a risk assessment. When comparing two potential investments, we recommend comparing similar equities with homogenous growth potential and valuation from related markets to determine which investment holds the most risk.
Story Coverage note for Zelira Therapeutics
The number of cover stories for Zelira Therapeutics depends on current market conditions and Zelira Therapeutics' risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Zelira Therapeutics is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Zelira Therapeutics' long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Other Macroaxis Stories
Our audience includes start-ups and big corporations as well as marketing, public relation firms, and advertising agencies, including technology and finance journalists. Our platform and its news and story outlet are popular among finance students, amateur traders, self-guided investors, entrepreneurs, retirees and baby boomers, academic researchers, financial advisers, as well as professional money managers - a very diverse and influential demographic landscape united by one goal - build optimal investment portfolios
Story Categories
Currently Trending Categories
Other Information on Investing in Zelira OTC Stock
Zelira Therapeutics financial ratios help investors to determine whether Zelira OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Zelira with respect to the benefits of owning Zelira Therapeutics security.